ea0032p103 | Bone and Osteoporosis | ECE2013
Mormando Marilda
, Fusco Alessandra
, Pola Enrico
, Piacentini Serena
, Nasto Luigi Aurelio
, Colangelo Debora
, Chiloiro Sabrina
, Bianchi Antonio
, Pontecorvi Alfredo
, De Marinis Laura
Anabolic therapies represent a major advance in the management of severe osteoporosis. Parathyroid hormone (PTH) and human recombinant PTH peptide 134 (Teriparatide) demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in patients with osteoporosis when given for 1824 months. The intermittent administration of PTH or teriparatide stimulates osteoblastic function, improves bone architecture and has an additional analges...